Lintitript Uses, Dosage, Side Effects and more
Lintitript is a new, highly specific and potent CCK-A receptor antagonist.
Lintitript SR 27897 is a selective cholecystokinin type A (CCK-A) receptor antagonist. In February 2000, Sanofi announced that it was halting development of the drug for appetite disorders, and in September 2002, Sanofi announced that it had stopped investigation all together.
| Attribute | Details |
|---|---|
| Trade Name | Lintitript |
| Generic | Lintitript |
| Lintitript Other Names | Lintitript |
| Type | |
| Formula | C20H14ClN3O3S |
| Weight | Average: 411.861 Monoisotopic: 411.044439726 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
For the treatment of pancreatic cancer and appetite disorders.
How Lintitript works
Cholecystokinin (CCK) modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. Lintitript antagonizes the effect of cholecystokinin by binding to the cholecystokinin type A (CCK-A) receptor. This action presumably alters feeding habits, however the exact mechanism of action is not known.
